A Self-Regenerating Mixed-Valence FeOx-TiO2 Nanoplatform for Mitochondrion-Targeted Triple-Modal Cancer Therapy
International Journal of Nanomedicine · 2026
DOI: 10.2147/ijn.s629321 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2026. Verfasst von Yongzhi Xia und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Bengbu Medical University, Bengbu, Anhui, 233030, People's Republic of China. Hauptthemen laut MEDLINE: Mitochondria, Photosensitizing Agents, Titanium, Ferric Compounds. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
Reactive oxygen species (ROS) cancer therapy is limited by short ROS lifetime, restricted diffusion, and lack of subcellular targeting. Current approaches physically mix independent components, causing complexity and decoupled actions. To overcome these barriers, we developed a mitochondrion-targeted nanoplatform (FTDT) built on a FeOₓ-TiO2 composite core with intrinsic mixed-valence Fe2⁺/Fe3⁺ pairs. The FT core acts as photosensitizer, while FeOₓ provides catalase- and peroxidase-like activities, integrating self-oxygenation, antioxidant depletion, self-amplifying redox cycling, photosensitization, photothermal conversion, and organelle anchoring into a single entity.
Methods
FTDT was synthesized via a hydrothermal method, PDA coating, and TPP conjugation. Mixed-valence state was confirmed by XPS. Catalase- and peroxidase-like activities were evaluated by O2 and ∙OH detection. UV-Vis-NIR spectroscopy characterized optical absorption. Photothermal conversion was measured under 808 nm laser. 1O2 generation was detected using DPBF. Intracellular hypoxia, ROS, mitochondrial targeting, membrane potential, and lysosomal integrity were assessed by fluorescence microscopy. Cytotoxicity and in vivo efficacy were evaluated in A549 cells and xenograft mice.
Results
FTDT showed a self-amplifying cycle: Fe2⁺ drives ∙OH generation, Fe3⁺ consumes GSH and regenerates Fe2⁺; Fe3⁺ from Fenton reaction replenishes the Fe3⁺ pool. The core converted H2O2 to O2. FT core with PDA-enabled NIR absorption allowed 1O2 generation and photothermal conversion. TPP enabled mitochondrial localization, inducing dysfunction, lipid peroxidation, and lysosomal disruption, leading to cell death. In vitro and in vivo studies confirmed antitumor efficacy with good biocompatibility.
Conclusion
By unifying self-oxygenation, antioxidant depletion, self-amplifying redox cycling, photosensitization, photothermal conversion, and organelle anchoring, FTDT offers a clinically translatable strategy to overcome key barriers in ROS-based cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Bengbu Medical University, Bengbu, Anhui, 233030, People's Republic of China.
- School of Laboratory Medicine, Bengbu Medical University, Bengbu, Anhui, 233030, People's Republic of China.
- Anhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Bengbu Medical University, Bengbu, Anhui, 233030, People's Republic of China.
- Department of Microbiology and Parasitology, Bengbu Medical University, Bengbu, Anhui, 233030, People's Republic of China.
Zitieren
APA
Xia, Y., Wang, M., Zhou, Y., Wei, R., Wang, Y., Hua, L., Fang, Q., & Chen, Y. (2026). A Self-Regenerating Mixed-Valence FeOx-TiO2 Nanoplatform for Mitochondrion-Targeted Triple-Modal Cancer Therapy. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s629321
Vancouver
Xia Y, Wang M, Zhou Y, Wei R, Wang Y, Hua L, et al. A Self-Regenerating Mixed-Valence FeOx-TiO2 Nanoplatform for Mitochondrion-Targeted Triple-Modal Cancer Therapy. International Journal of Nanomedicine. 2026. doi:10.2147/ijn.s629321
BibTeX
@article{Xia2026,
author = {Xia, Yongzhi and Wang, Mengqin and Zhou, Yanyan and Wei, Ruiqi and Wang, Yijie and Hua, Lijuan and Fang, Qiang and Chen, Yan},
title = {A Self-Regenerating Mixed-Valence FeOx-TiO2 Nanoplatform for Mitochondrion-Targeted Triple-Modal Cancer Therapy},
journal = {International Journal of Nanomedicine},
year = {2026},
doi = {10.2147/ijn.s629321}
}
EUVIMED